Skip to main content
. Author manuscript; available in PMC: 2017 Oct 12.
Published in final edited form as: Semin Hematol. 2016 May 12;53(3):180–185. doi: 10.1053/j.seminhematol.2016.05.010

Figure 3.

Figure 3

A randomized, double-blind, placebo-controlled, phase 3 trial of brentuximab vedotin (BV) as consolidation therapy after autologous stem cell transplant in patients with high risk Hodgkin Lymphoma (AETHERA): Progression-free survival (PFS) per investigator 3 years since last patient randomized. Includes clinical assessments of lymphoma.